Top

Published in:

Open Access 01-12-2015 | Research article

Comparison of quality-of-care measures in U.S. patients with end-stage renal disease secondary to lupus nephritis vs. other causes

Published in: BMC Nephrology | Issue 1/2015

Abstract

Background

Patients with end-stage renal disease (ESRD) due to lupus nephritis (LN-ESRD) may be followed by multiple providers (nephrologists and rheumatologists) and have greater opportunities to receive recommended ESRD-related care. We aimed to examine whether LN-ESRD patients have better quality of ESRD care compared to other ESRD patients.

Methods

Among incident patients (7/05–9/11) with ESRD due to LN (n = 6,594) vs. other causes (n = 617,758), identified using a national surveillance cohort (United States Renal Data System), we determined the association between attributed cause of ESRD and quality-of-care measures (pre-ESRD nephrology care, placement on the deceased donor kidney transplant waitlist, and placement of permanent vascular access). Multivariable logistic and Cox proportional hazards models were used to estimate adjusted odds ratios (ORs) and hazard ratios (HRs).

Results

LN-ESRD patients were more likely than other ESRD patients to receive pre-ESRD care (71% vs. 66%; OR = 1.68, 95% CI 1.57-1.78) and be placed on the transplant waitlist in the first year (206 vs. 86 per 1000 patient-years; HR = 1.42, 95% CI 1.34–1.52). However, only 24% had a permanent vascular access (fistula or graft) in place at dialysis start (vs. 36%; OR = 0.63, 95% CI 0.59–0.67).

Conclusions

LN-ESRD patients are more likely to receive pre-ESRD care and have better access to transplant, but are less likely to have a permanent vascular access for dialysis, than other ESRD patients. Further studies are warranted to examine barriers to permanent vascular access placement, as well as morbidity and mortality associated with temporary access, in patients with LN-ESRD.

Astor BC, Eustace JA, Powe NR, Klag MJ, Sadler JH, Fink NE, et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE Study. Am J Kidney Dis. 2001;38:494–501.CrossRefPubMed

Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, et al. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol. 2002;55:711–6.CrossRefPubMed

Winkelmayer WC, Glynn RJ, Levin R, Owen Jr W, Avorn J. Late referral and modality choice in end-stage renal disease. Kidney Int. 2001;60:1547–54.CrossRefPubMed

Winkelmayer WC, Glynn RJ, Levin R, Mittleman MA, Pliskin JS, Avorn J. Late nephrologist referral and access to renal transplantation. Transplantation. 2002;73:1918–23.CrossRefPubMed

Winkelmayer WC, Owen Jr WF, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14:486–92.CrossRefPubMed

Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479–86.CrossRefPubMed

Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis. 2003;41:310–8.CrossRefPubMed

Kazmi WH, Obrador GT, Khan SS, Pereira BJ, Kausz AT. Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant. 2004;19:1808–14.CrossRefPubMed

Hasegawa T, Bragg-Gresham JL, Yamazaki S, Fukuhara S, Akizawa T, Kleophas W, et al. Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol. 2009;4:595–602.CrossRefPubMedPubMedCentral

10.

Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. J Am Med Assoc. 1993;270:1339–43.CrossRef

11.

Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis. 1994;24:59–64.CrossRefPubMed

12.

Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.CrossRefPubMed

13.

Kutner NG. Improving compliance in dialysis patients: does anything work? Semin Dial. 2001;14:324–7.CrossRefPubMed

14.

Evans RW, Manninen DL, Garrison Jr LP, Hart LG, Blagg CR, Gutman RA, et al. The quality of life of patients with end-stage renal disease. N Engl J Med. 1985;312:553–9.CrossRefPubMed

15.

United States Renal Data System. USRDS 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2013. Available at: www.usrds.org.

16.

Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int. 2002;61:305–16.CrossRefPubMed

17.

Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–35.PubMed

18.

Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–22.CrossRefPubMed

19.

Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001;60:1443–51.CrossRefPubMed

20.

Woods JD, Port FK. The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant. 1997;12:657–9.CrossRefPubMed

21.

Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis. 2003;42:1013–9.CrossRefPubMed

22.

Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol. 2004;15:477–86.CrossRefPubMed

23.

Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002;62:620–6.CrossRefPubMed

24.

Office of Disease Prevention and Health Promotion. Healthy people 2020. Washington, DC: U.S. Department of Health and Human Services; 2015. Available at: www.healthypeople.gov.

25.

Centers for Medicare & Medicaid Services. Final CY 2014 end-stage renal disease prospective payment system. Department of Health and Human Services; Reg. No. CMS-1526-F, 12/2/2013. Available at: http://www.gpo.gov/fdsys/pkg/FR-2013-1202/pdf/2013-28451.pdf.

26.

Plantinga L, Drenkard C, Patzer R, Klein M, Kramer M, Pastan S, et al. Sociodemographic and geographic predictors of quality of care in U.S. patients with end-stage renal disease due to lupus nephritis. Arthritis Rheumatol. 2015;67:761–72.CrossRefPubMed

27.

Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63:1681–8.CrossRefPubMedPubMedCentral

28.

Hiraki LT, Lu B, Alexander SR, Shaykevich T, Alarcon GS, Solomon DH, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995–2006. Arthritis Rheum. 2011;63:1988–97.CrossRefPubMedPubMedCentral

29.

McClellan AC, Luthi JC, Lynch JR, Soucie JM, Kulkarni R, Guasch A, et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol. 2012;159:360–7.CrossRefPubMedPubMedCentral

30.

Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797–808.CrossRef

31.

Mohan S, Huff E, Wish J, Lilly M, Chen SC, McClellan WM. Recovery of renal function among ESRD patients in the US medicare program. PLoS One. 2013;8:e83447.CrossRefPubMedPubMedCentral

32.

Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244–54.CrossRefPubMed

33.

McAdams-DeMarco MA, James N, Salter ML, Walston J, Segev DL. Trends in kidney transplant outcomes in older adults. J Am Geriatr Soc. 2014;62:2235–42.PubMedPubMedCentral

34.

Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014;66:390–6.CrossRefPubMedPubMedCentral

35.

O’Hare AM, Batten A, Burrows NR, Pavkov ME, Taylor L, Gupta I, et al. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis. 2012;59:513–22.CrossRefPubMedPubMedCentral

36.

Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61:1502–9.CrossRefPubMed

37.

Ashby VB, Port FK, Wolfe RA, Wynn JJ, Williams WW, Roberts JP, et al. Transplanting kidneys without points for HLA-B matching: consequences of the policy change. Am J Transplant. 2011;11:1712–8.CrossRefPubMed

38.

Hall EC, Massie AB, James NT, Garonzik Wang JM, Montgomery RA, Berger JC, et al. Effect of eliminating priority points for HLA-B matching on racial disparities in kidney transplant rates. Am J Kidney Dis. 2011;58:813–6.CrossRefPubMed

39.

Contreras G, Mattiazzi A, Guerra G, Ortega LM, Tozman EC, Li H, et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol. 2010;21:1200–7.CrossRefPubMedPubMedCentral

40.

Ward MM. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int. 2000;57:2136–43.CrossRefPubMed

41.

Bunnapradist S, Chung P, Peng A, Hong A, Chung P, Lee B, et al. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the organ procurement and transplantation network database. Transplantation. 2006;82:612–8.CrossRefPubMed

42.

Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med. 1996;101:100–7.CrossRefPubMed

43.

Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus nephritis. J Nephrol. 2003;16:787–91.PubMed

44.

Plantinga LC, Patzer RE, Drenkard C, Kramer MR, Klein M, Lim SS, et al. Association of time to kidney transplantation with graft failure among U.S. patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res. 2015;67:571–81.CrossRef

45.

Lynch JR, Mohan S, McClellan WM. Achieving the goal: results from the fistula first breakthrough initiative. Curr Opin Nephrol Hypertens. 2011;20:583–92.CrossRefPubMed

46.

Vassalotti JA, Jennings WC, Beathard GA, Neumann M, Caponi S, Fox CH, et al. Fistula first breakthrough initiative: targeting catheter last in fistula first. Semin Dial. 2012;25:303–10.CrossRefPubMed

47.

Sule SD, Fadrowski JJ, Fivush BA, Gorman G, Furth SL. Reduced albumin levels and utilization of arteriovenous access in pediatric patients with systemic lupus erythematosus (SLE). Pediatr Nephrol. 2007;22:2041–6.CrossRefPubMed

48.

Sule SD, Fadrowski JJ, Fivush BA, Neu AM, Furth SL. Persistent low albumin and temporary vascular access in pediatric patients with SLE on hemodialysis. Pediatr Nephrol. 2009;24:1981–7.CrossRefPubMedPubMedCentral

49.

Sato Y, Miyamoto M, Sueki S, Sakurada T, Kimura K, Nakazawa R, et al. Risk factors associated with inadequate veins for placement of arteriovenous fistulas for hemodialysis. J Artif Organs. 2013;16:469–74.CrossRefPubMed

50.

Muringai T, Noble H, McGowan A, Channey M. Dialysis access and the impact on body image: role of the nephrology nurse. Br J Nurs. 2008;17:362–6.CrossRefPubMed

51.

Casey JR, Hanson CS, Winkelmayer WC, Craig JC, Palmer S, Strippoli GF, et al. Patients’ perspectives on hemodialysis vascular access: a systematic review of qualitative studies. Am J Kidney Dis. 2014;64(6):937–53.CrossRefPubMed

52.

Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001.

53.

Layton JB, Hogan SL, Jennette CE, Kenderes B, Krisher J, Jennette JC, et al. Discrepancy between medical evidence form 2728 and renal biopsy for glomerular diseases. Clin J Am Soc Nephrol. 2010;5:2046–52.CrossRefPubMedPubMedCentral

54.

Salter ML, Orandi B, McAdams-DeMarco MA, Law A, Meoni LA, Jaar BG, et al. Patient- and provider-reported information about transplantation and subsequent waitlisting. J Am Soc Nephrol. 2014;25:2871–7.CrossRefPubMedPubMedCentral

Title: Comparison of quality-of-care measures in U.S. patients with end-stage renal disease secondary to lupus nephritis vs. other causes
Publication date: 01-12-2015
Published in: BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-015-0037-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparison of quality-of-care measures in U.S. patients with end-stage renal disease secondary to lupus nephritis vs. other causes

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease

Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study

Resilience and quality of life in 161 living kidney donors before nephrectomy and in the aftermath of donation: a naturalistic single center study

Urinary adiponectin and albuminuria in non-diabetic hypertensive patients: an analysis of the ESPECIAL trial

The TALKS study to improve communication, logistical, and financial barriers to live donor kidney transplantation in African Americans: protocol of a randomized clinical trial

Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page